[{"title": "Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised \u2026", "link": "https://www.thelancet.com/journals/laneur/article/PIIS1474-4422\\(24\\)00216-3/abstract", "details": "LH van den Berg, JD Rothstein, PJ Shaw, S Babu\u2026 - The Lancet Neurology, 2024", "abstract": "Background Hexanucleotide repeat expansion of C9orf72 is a common genetic cause of amyotrophic lateral sclerosis (ALS). No C9orf72-targeted treatments are available. BIIB078 is an investigational antisense oligonucleotide targeting C9orf72 \u2026"}, {"title": "Response letter to: a homozygous p. Val120Leu (c. 358G> C) SOD1 mutation led to slowly progressive amyotrophic lateral sclerosis in a Brazilian family", "link": "https://www.tandfonline.com/doi/pdf/10.1080/21678421.2024.2374372", "details": "PLGSB Lima, EM Couto, PR N\u00f3brega - Amyotrophic Lateral Sclerosis and \u2026, 2024", "abstract": "Dear Editor, We read with interest the article by Fernandes and colleagues (1) where they presented a case of slowly progressive amyotrophic lateral sclerosis (ALS) associated with a p. Val120Leu (c. 358G> C) SOD1 variant in homozygosis. In this \u2026"}]
